4445-40-3

Basic information

• Product Name: 4'-AMINO-BIPHENYL-3-CARBOXYLIC ACID
• Synonyms: ART-CHEM-BB B025031;4'-AMINO[1,1'-BIPHENYL]-3-CARBOXYLIC ACID;4'-AMINO-BIPHENYL-3-CARBOXYLIC ACID;AKOS BAR-0151;AKOS B025031;VITAS-BB TBB000334;2-Amino-5-phenylbenzoic acid
• CAS NO: 4445-40-3
• Molecular Formula: C₁₃H₁₁NO₂
• Molecular Weight: 213.23
• Mol File: 4445-40-3.mol
• Article Data: 10

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 4'-AMINO-BIPHENYL-3-CARBOXYLIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 4'-AMINO-BIPHENYL-3-CARBOXYLIC ACID(4445-40-3)
• EPA Substance Registry System: 4'-AMINO-BIPHENYL-3-CARBOXYLIC ACID(4445-40-3)

Safety Data

• Hazard Codes: Xn
• Statements: 22
• Hazardous Substances Data: 4445-40-3(Hazardous Substances Data)

Usage

General Description

4'-Amino-biphenyl-3-carboxylic acid is a chemical compound that is used in the manufacturing of pharmaceuticals and agrochemicals. It is an intermediate in the synthesis of a variety of drugs, including antihypertensive and antidiabetic medications. 4'-AMINO-BIPHENYL-3-CARBOXYLIC ACID is also used as a starting material for the synthesis of dyes, pigments, and other organic compounds. Additionally, 4'-amino-biphenyl-3-carboxylic acid is a potential carcinogen and its exposure is regulated in many countries due to its potential health risks. Overall, this chemical plays a vital role in the synthesis of various important products, but its usage is strictly regulated due to its potential health hazards.

Upstream product

• 92-95-5 4-biphenyl isocyanate 
• 109496-98-2 5‐phenylindoline‐2,3‐dione 
• 5152-76-1 N-chloro-2'-methylacetanilide 
• 69314-47-2 3-methyl-4-nitrobiphenyl 
• 5794-88-7 5-Bromo-2-aminobenzoic acid 
• 98-80-6 phenylboronic acid 
• 63040-30-2 N-(3-methyl-biphenyl-4-yl)-acetamide 
• 540-37-4 p-aminoiodobenzene 
• 20780-76-1 5-iodoisatin 
• 584-08-7 potassium carbonate 
• 5326-47-6 2-amino-5-iodobenzoic acid 
• 243989-52-8 4-amino-biphenyl-3-carboxylic acid methyl ester 
• 134-20-3 2-carbomethoxyaniline 
• 851314-03-9 methyl 5-bromo-2-((tert-butoxycarbonyl)amino)benzoate 

Downstream Products

• 206190-28-5 6-phenylquinazolin-4(3H)-one 
• 1046152-56-0 C₂₆H₁₈O₄Se₂ 
• 1237744-77-2 2-methyl-6-phenyl-4H-benzo[d][1,3]oxazin-4-one 

Relevant articles and documents

Design, synthesis and biological evaluation of novel o-aminobenzamide derivatives as potential anti-gastric cancer agents in vitro and in vivo

Although gastric cancer has become a major public health problem, oral agents applied in clinics for gastric cancer therapy are scarce. Therefore, to explore new oral chemical entities with high efficiency and low toxicity, 41 o-aminobenzamide derivatives based on the scaffolds of MS-275 and SAHA were designed, synthesized, and evaluated for their anti-gastric cancer abilities in vitro and in vivo. Structure-activity relationships were discussed, leading to the identification of compounds F8 (IC50 = 0.28 μM against HGC-27 cell) and T9 (IC50 = 1.84 μM against HGC-27 cell) with improved cytotoxicity, anti-gastric cancer proliferation potency, induction of cell apoptosis and cell cycle arrest ability, inhibition of cell migration and invasion. What is worth mentioning is that compound F8 was more efficient and less toxic than the positive drug capecitabine in vivo on the HGC-27-xenograft model. Meanwhile, compound F8 exhibited suitable pharmacokinetic properties and less acute toxicity (LD50 > 1000 mg/kg). Besides, western blotting analysis, IHC analysis, differentially expressed proteins analysis and ABPP experiment indicated that compound F8 could modulate molecular pathways involved in apoptosis and cell cycle progression. Consequently, compound F8 is a strong candidate for the development of human gastric cancer therapy.

Anthranilic acid and derivatives thereof as well as synthesis method and application thereof

In the reaction solvent, o-methyl (hetero) aryl nitro compound is taken as a reaction raw material and is used for water. The anthranilic acid and its derivatives are synthesized by the action of a catalyst, a base and an additive. The synthetic method has the advantages of cheap and easily available raw materials, simple reaction operation, high yield and excellent functional group tolerance, and provides a simple and efficient method for synthesizing o-aminobenzoic acid which is widely used in the aspects of dyes, medicines, pesticides, spices and the like. The invention further discloses the anthranilic acid and derivatives and application thereof, and has a wide application prospect.

Discovery of the first Mycobacterium tuberculosis MabA (FabG1) inhibitors through a fragment-based screening

Mycobacterium tuberculosis (M.tb), the etiologic agent of tuberculosis, remains the leading cause of death from a single infectious agent worldwide. The emergence of drug-resistant M.tb strains stresses the need for drugs acting on new targets. Mycolic acids are very long chain fatty acids playing an essential role in the architecture and permeability of the mycobacterial cell wall. Their biosynthesis involves two fatty acid synthase (FAS) systems. Among the four enzymes (MabA, HadAB/BC, InhA and KasA/B) of the FAS-II cycle, MabA (FabG1) remains the only one for which specific inhibitors have not been reported yet. The development of a new LC-MS/MS based enzymatic assay allowed the screening of a 1280 fragment-library and led to the discovery of the first small molecules that inhibit MabA activity. A fragment from the anthranilic acid series was optimized into more potent inhibitors and their binding to MabA was confirmed by 19F ligand-observed NMR experiments.